Cytokinetics (CYTK) Earnings Date & Reports

Key Takeaways

• Cytokinetics is expected to report Q2 2026 results on or around July 30, 2026, marking its second quarter as a commercial-stage biopharmaceutical company following the U.S. launch of Myqorzo (aficamten) in late January.
• Consensus EPS estimates for Q2 2026 stand at approximately -$1.64 per share, compared to -$1.12 reported in Q2 2025 and -$1.67 in Q1 2026, according to analyst estimates tracked by TipRanks and other data providers.
• Revenue is projected to land around $16.5 million to $17.7 million, with investors closely tracking Myqorzo net product revenue, which reached $4.8 million over roughly nine weeks in Q1 2026.
• The Q2 period includes the highly anticipated ACACIA-HCM Phase 3 trial readout, which met both primary endpoints in non-obstructive hypertrophic cardiomyopathy (nHCM), potentially doubling Myqorzo's addressable market.
• Wall Street remains broadly bullish, with 22 analysts maintaining a consensus "Buy" rating and an average 12-month price target near $107, implying roughly 33% upside from recent trading levels around $80.
• Cash runway and expense discipline remain in focus, with Cytokinetics holding approximately $1.1 billion in cash and investments as of March 31, 2026, against full-year combined R&D and SG&A (selling, general, and administrative) guidance of $830 million to $870 million.

Earnings Context and Why It Matters

Cytokinetics' Q2 2026 report represents a pivotal moment in the company's transition from a clinical-stage biotech to a commercial enterprise. The U.S. Food and Drug Administration (FDA) approved Myqorzo in December 2025 for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), and the drug became commercially available to patients in late January 2026. Q1 results showed encouraging early traction, with approximately 1,100 patients on therapy by the end of April and over $4.8 million in net product revenue. Q2 will be the first full quarter of commercial sales, offering a clearer picture of launch trajectory. Layered on top of that, positive ACACIA-HCM trial results in non-obstructive HCM, released during the quarter, have materially expanded the drug's potential market opportunity and elevated investor expectations.

Earnings Expectations

Wall Street expects Cytokinetics to report a net loss of roughly $1.64 per share for Q2 2026, based on consensus estimates from TipRanks. Revenue estimates cluster between $16.5 million and $17.7 million. For context, Q2 2025 reported revenue of $66.8 million, but that figure was inflated by a one-time $52.4 million technology transfer payment from Bayer, making year-over-year comparisons less meaningful. Excluding that milestone, underlying revenue stood at approximately $2.0 million in Q2 2025.

The key commercial metric investors will scrutinize is Myqorzo net product revenue. Q1 2026 delivered $4.8 million over roughly nine weeks — a partial-quarter result. A full quarter of sales, combined with growing prescriber momentum (over 425 healthcare providers had prescribed Myqorzo through April), suggests a sequential revenue step-up is expected. Beyond product sales, collaboration and milestone revenue from partners Bayer and Sanofi may also contribute meaningfully to the top line, though the timing and quantum of milestone recognition is harder to predict.

On the expense side, management has guided to full-year 2026 GAAP combined R&D and SG&A expenses of $830 million to $870 million, reflecting significant commercial infrastructure investment. Q1 operating expenses totaled roughly $200 million, and a similar quarterly run rate is anticipated. Cytokinetics has historically demonstrated a mixed track record against consensus — Q1 2026 EPS matched estimates, while Q4 2025 beat by $0.06 — so modest variability is possible.

AI Screener

For investors seeking to identify new opportunities alongside earnings-driven names like Cytokinetics, Tickeron's AI Screener offers a powerful AI-driven stock and ETF discovery platform. The tool enables traders and investors to filter thousands of securities using customizable criteria including technical patterns, fundamental metrics, trend strength, volatility parameters, and proprietary AI-powered signals. Users can scan by industry, market capitalization, technical indicators, price patterns, and performance metrics to surface trade ideas, breakout candidates, and trending stocks far more efficiently than manual screening. Whether searching for pre-earnings momentum or post-earnings setups, the AI Screener helps streamline the discovery process in a complex market environment.

Market Reaction and Investor Sentiment

Cytokinetics shares have surged roughly 33% year-to-date through late July 2026, driven by Myqorzo launch optimism and the positive ACACIA-HCM data readout. The stock currently trades near its 52-week high, reflecting elevated investor expectations heading into the Q2 report. Analyst sentiment leans heavily bullish: of 22 analysts covering the stock, 20 rate it "Buy" or "Strong Buy," while 2 maintain "Hold" ratings. Recent price target increases from firms including Mizuho ($118), UBS (upgraded to Buy, $115 target), and RBC Capital ($117) underscore growing conviction in the Myqorzo commercial story. However, the stock's elevated valuation also raises the bar for the earnings report. Any sign of slower-than-expected Myqorzo prescription growth, payer access friction, or disappointing revenue could trigger near-term volatility. Historically, CYTK has moved an average of roughly 1% to 3% in the week following earnings, though the expanding commercial narrative may amplify the reaction this quarter.

Forward Outlook and Key Factors to Monitor

The Q2 earnings call will be closely parsed for forward-looking commentary across several critical fronts. First and most importantly, management's tone on Myqorzo launch trajectory — including updated patient numbers, prescriber breadth, and conversion rates from free to paid prescriptions — will shape the commercial narrative for the remainder of 2026. Q1 exit metrics showed over 70% of dispensed patients on paid prescriptions with average conversion in under two weeks, and sustaining or improving those figures is essential.

Second, the ACACIA-HCM data in non-obstructive HCM opens a substantial market expansion opportunity. Management has indicated plans for regulatory discussions and a potential supplemental New Drug Application (sNDA) submission. Any concrete timelines shared during the call would be a significant catalyst for the stock.

Third, the European commercial launch, expected to begin in Germany during Q2 2026, represents the next geographic growth phase. Updates on pricing negotiations, Health Technology Assessment (HTA) dossier submissions across six EU markets, and initial European demand signals will be important.

Fourth, the MAPLE-HCM sNDA has a PDUFA (Prescription Drug User Fee Act) target date of November 14, 2026, which could broaden the Myqorzo label. Finally, cash burn remains a key variable — the company ended Q1 with $1.1 billion, and investors will want assurance that the runway comfortably supports simultaneous commercial buildout and pipeline advancement through at least the next 18 to 24 months. Operational updates on pipeline programs such as COMET-HF, AMBER-HFpEF, and CEDAR-HCM will round out the strategic picture.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations